Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
Early dose-escalation data from Phase…Read More
You might also be interested in reading Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D.